Q32 Bio任命新任首席医学官与首席开发官，为bempikibart注册性试验做准备

----- d158730d8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 14, 2026
Q32 Bio Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38433
47-3468154
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
830 Winter Street
Waltham
,
Massachusetts
02451
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
781
999-0232
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
QTTB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On September 14, 2026, Q32 Bio Inc. (the ”Company“) issued a press release announcing the appointment of José Trevejo, M.D., Ph.D., as the Company’s Chief Medical Officer and Ellie Hershberger, Pharm.D., as the Company’s Chief Development Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information set forth under Item 7.01 (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On September 14, 2026, the Company announced the appointment of José Trevejo, M.D., Ph.D., as its Chief Medical Officer. Prior to joining the Company, Dr. Trevejo served as Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Therapeutics, Inc. (“Enveda”), an
AI-enabled
drug discovery company, where he helped advance multiple clinical-stage candidates, including a Phase 2 candidate for atopic dermatitis, from July 2024 to September 2026. Prior to Enveda, Dr. Trevejo was Chief Medical Officer at Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) from February 2022 to February 2024, where he helped lead the FDA approval and successful launch of XDEMVY
®
, the first
FDA-approved
treatment for Demodex blepharitis. Before that, he served as Chief Development Officer at Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) from October 2020 to February 2022, a biotechnology company advancing genetic medicines for rare diseases. Dr. Trevejo received his M.D. and Ph.D. from the Cornell-Rockefeller-Sloan Kettering
Tri-Institutional
M.D.-Ph.D.
Program and completed his residency and specialty training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center, both Harvard Medical School affiliates.
Also on September 14, 2026, the Company announced the appointment of Ellie Hershberger, Pharm. D. as its Chief Development Officer. Prior to joining the Company, Dr. Hershberger was a consultant at EMH Consulting LLC from January 2023 to September 2026. Previously, she served as Chief Development Officer of Adagio Therapeutics, Inc. (“Adagio”), now Invivyd, Inc. (Nasdaq: IVVD) from June 2020 to January 2023, where she led the development organization and advanced the company’s lead monoclonal antibody candidate from
IND-enabling
activities through Phase 3 clinical development. As a member of the executive team, she also helped build the development infrastructure to support global approval and contributed to the company’s successful initial public offering. Following the completion of her Pharm.D. degree at Ferris State University, Dr. Hershberger completed a Research Fellowship in pharmacokinetics and pharmacodynamics at Wayne State University.
Item 9.01 Financial Statements and Exhibits.
99.1
Press Release issued by Q32 Bio Inc. on September 14, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Q32 Bio Inc.
Date: September 14, 2026
By:
/s/ Jodie Morrison
Jodie Morrison
Chief Executive Officer

----- d158730dex991.htm -----
EX-99.1
2
d158730dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger,
Pharm.D., as Chief Development Officer
— Dr. Trevejo is a physician-scientist and biotechnology executive with over 20
years of experience spanning dermatology and late-stage clinical development —
— Dr. Hershberger is a drug
development leader with over 30 years of experience spanning late-stage development operations and regulatory
strategy —
WALTHAM, Mass., September
14, 2026
– Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical-stage
biotechnology company focused on developing innovative therapies for alopecia areata (“AA”) and other autoimmune and inflammatory diseases, today announced the appointment of José Trevejo, M.D., Ph.D.,
as Chief Medical
Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer.
“José and Ellie join Q32 Bio at a pivotal moment as we transition
into a late clinical stage company in line with our preparations to advance bempikibart into a registration-directed program for severe or very severe alopecia areata and continue to evaluate expansion opportunities in additional alopecia areata
populations as well as other autoimmune and inflammatory indications,” said Jodie Morrison, Chief Executive Officer of Q32 Bio. “José is a seasoned biotechnology executive and exceptional physician-scientist with over 20 years of
leadership experience spanning dermatology, clinical pipeline strategy and late-stage clinical development, and Ellie brings more than 30 years of drug development expertise, with extensive experience overseeing late-stage development operations and
regulatory strategy. We are thrilled to welcome José and Ellie to the Q32 Bio team.”
“Bempikibart has shown encouraging results in
Part B of the
SIGNAL-AA
program in alopecia areata, demonstrating meaningful hair regrowth, early signs of durability in the
off-drug
period and a generally
well-tolerated safety profile. Based on the results to date, bempikibart has the potential to address key limitations of currently available therapies for alopecia areata,” said José Trevejo, M.D., Ph.D., Chief Medical Officer of Q32
Bio. “I look forward to working with the team to help make a meaningful difference for patients with alopecia areata and other autoimmune diseases where
IL-7
and TSLP signaling play a role.”
“This is an exciting time to join Q32 Bio. I look forward to working with the team as we build on
SIGNAL-AA
and
advance bempikibart into a registration-directed program in alopecia areata in the first half of 2027, and as we expand development into additional populations and indications,” said Ellie Hershberger, Pharm.D., Chief Development Officer of
Q32 Bio.
Prior to joining Q32 Bio, Dr. Trevejo served as Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Therapeutics, Inc.
(“Enveda”), an
AI-enabled
drug discovery company, where he helped advance multiple clinical-stage candidates, including a Phase 2 candidate for atopic dermatitis. Prior to Enveda, Dr. Trevejo
was Chief Medical Officer at Tarsus Pharmaceuticals, where he helped lead the FDA approval and successful launch of XDEMVY
®
, the first
FDA-approved
treatment for
Demodex
blepharitis. Before that, he served as Chief Development Officer at Rocket Pharmaceuticals, a biotechnology company advancing genetic medicines for rare diseases, and Chief Executive Officer and
founder of SmartPharm Therapeutics, a
non-viral
gene therapy company acquired by Sorrento Therapeutics in 2020. Earlier in his career, he held clinical
development leadership roles at Cyclerion Therapeutics (spun out of Ironwood Pharmaceuticals), Visterra, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his M.D. and Ph.D. from the Cornell-Rockefeller-Sloan Kettering
Tri-Institutional
M.D.-Ph.D.
Program and completed his residency and specialty training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center, both
Harvard Medical School affiliates.
Prior to joining Q32 Bio, Dr. Hershberger served as Chief Development Officer of Adagio Therapeutics, now
Invivyd, where she led the development organization and advanced the company’s lead monoclonal antibody candidate from
IND-enabling
activities through Phase 3 clinical development. As a member of the
executive team, she also helped build the development infrastructure to support global approval and contributed to the company’s successful initial public offering, which raised approximately $356 million in gross proceeds. Prior to
Adagio, Dr. Hershberger served as Executive Director and Head of Clinical Research at Visterra, where she led clinical development and regulatory strategy for multiple drug candidates. Before that, she held senior clinical development
leadership roles at Merck and Cubist Pharmaceuticals, where she led a cross-functional project team responsible for the global development, lifecycle management and commercialization of a lead antibiotic candidate across multiple indications.
Earlier in her career, she held clinical development roles at Pfizer and served as Director of the Clinical Research Center and Infectious Disease Laboratory at William Beaumont Hospital. Following the completion of her Pharm.D. degree,
Dr. Hershberger completed a Research Fellowship in pharmacokinetics and pharmacodynamics at Wayne State University.
About Q32 Bio
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to
re-balance
immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata
1
, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart
(ADX-914),
a fully human
anti-IL-7Rα
antibody that
re-regulates
adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2
program. The
IL-7
and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
1
National Alopecia Areata Foundation
Availability of Other Information About Q32 Bio
Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but
not limited to, Q32 Bio’s disclosures, investor presentations and FAQs, Securities and Exchange Commission (the “SEC”) filings, press releases, public conference call transcripts and webcast transcripts, as well
as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested
to review the information that it posts there on a regular basis. The contents of Q32 Bio’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This communication contains
forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are
forward-looking statements, including, among others, Q32 Bio’s beliefs, observations, expectations and assumptions regarding the topline data from Part B of the
SIGNAL-AA
Phase 2a clinical
trial and the anticipated timing of its data, the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart including plans and expectations for Part B of the
SIGNAL-AA
Phase 2a clinical trial, Q32 Bio’s expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio’s product candidates, including
bempikibart, and anticipated milestones, timing of anticipated registrational trials, data readouts and timing, the potential expansion of bempikibart into additional populations and indications, expectations and assumptions regarding the future of
its business, future plans and strategies; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Forward-looking statements are based on management’s current beliefs and assumptions, which are subject to risks and uncertainties and are not
guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio’s current beliefs and expectations for bempikibart,
including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner
than currently anticipated, Q32 Bio’s expectations regarding the sufficiency of its cash and cash equivalents to provide financial runway and that Q32 Bio may need additional funding to complete clinical studies, which may not be available on
favorable terms or at all and such other risks and uncertainties identified in Q32 Bio’s periodic, current and other filings with the SEC, including its Annual Report on Form
10-K
for the
year ended December 31, 2025 and any subsequent filings with the SEC, which are available at the SEC’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32
Bio’s results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio’s stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contacts:
Investors: Brendan Burns
Senior Director, Investor Relations and
Corporate Communications
Q32 Bio
bburns@q32bio.com
Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com